In my opinion, we're not yet at the point where developments in regenetive medicine pose major competition to organovo. Instead, I feel any developments are helpful to them, as the whole sector needs to take off in order for organovo to be successful. The hurdles of the technology they are working to develop are too great for any one entity to tackle on their own, and onvo's going to need all the help they can get. The ability to produce functional human tissues is something the whole world wants/needs, and many research organizations are dedicated to making it happen as soon as possible. Onvo is in a good position to bring these developments to the market, or at least has valuable patent rights that will be essential to whoever does bring it to market.